secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moderna, Inc. (MRNA)
CIK:        0001682852
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001682852-26-000007
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moderna reports prelim 2025 rev ~$1.9B, cuts OpEx guidance, expects flu/COVID combo approvals in 2026
--------------------------------------------------------------------------------

- 2025 preliminary revenue ~$1.9B ($100M above midpoint); GAAP OpEx $5.0-5.2B (improved $200M).
- Year-end cash ~$8.1B including $0.6B draw from new $1.5B Ares term loan facility.
- 2026 targets: up to 10% revenue growth, $4.9B GAAP OpEx; 2027 OpEx $4.2-4.6B, path to cash breakeven 2028.
- Expects 2026 approvals of flu vaccine mRNA-1010 and flu/COVID combo mRNA-1083; multiple pivotal readouts in oncology/rare disease.
- Closed $1.5B term loan from Ares; CEPI commits $54.3M for H5 pandemic flu vaccine Phase 3 trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682852/000168285226000007/0001682852-26-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682852/000168285226000007/mrna-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001682852-26-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer